Skip to main content
SpringerLink
Log in

Anti-Angiogenic Activity of Selected Receptor Tyrosine Kinase Inhibitors, PD166285 and PD173074: Implications for Combination Treatment with Photodynamic Therapy

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Angiogenesis, the formation of new blood vessels from an existing vasculature, is requisite for tumor growth. It entails intercellular coordination of endothelial and tumor cells through angiogenic growth factor signaling. Interruption of these events has implications in the suppression of tumor growth. PD166285, a broad-spectrum receptor tyrosine kinase (RTK) inhibitor, and PD173074, a selective FGFR1TK inhibitor, were evaluated for their anti-angiogenic activity and anti-tumor efficacy in combination with photodynamic therapy (PDT). To evaluate the anti-angiogenic and anti-tumor activities of these compounds, RTK assays, in vitro tumor cell growth and microcapillary formation assays, in vivo murine angiogenesis and anti-tumor efficacy studies utilizing RTK inhibitors in combination with photodynamic therapy were performed. PD166285 inhibited PDGFR-β-, EGFR-, and FGFR1TKs and c-src TK by 50% (IC50) at concentrations between 7−85nM. PD173074 displayed selective inhibitory activity towards FGFR1TK at 26nM. PD173074 demonstrated (>100 fold) selective growth inhibitory action towards human umbilical vein endothelial cells compared with a panel of tumor cell lines. Both PD166285 and PD173074 (at 10nM) inhibited the formation of microcapillaries on Matrigel-coated plastic. In vivo anti-angiogenesis studies in mice revealed that oral administration (p.o.) of either PD166285 (1−25 mg/kg) or PD173074 (25−100 mg/kg) generated dose dependent inhibition of angiogenesis. Against a murine mammary 16c tumor, significantly prolonged tumor regressions were achieved with daily p.o. doses of PD166285 (5−10 mg/kg) or PD173074 (30−60 mg/kg) following PDT compared with PDT alone (p<0.001). Many long-term survivors were also noted in combination treatment groups. PD166285 and PD173074 displayed potent anti-angiogenic and anti-tumor activity and prolonged the duration of anti-tumor response to PDT. Interference in membrane signal transduction by inhibitors of specific RTKs (e.g. FGFR1TK) should result in new chemotherapeutic agents having the ability to limit tumor angiogenesis and regrowth following cytoreductive treatments such as PDT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tronick SR, Aaronson SA: Growth factors and signal transduction. In: J. Mendelsohn, P. M. Howley, M. A. Israel and L. A. Liotta editors. The Molecular Basis of Cancer. Philadelphia: W.B. Saunders Co.: p. 117–40, 1995

    Google Scholar 

  2. Merenmies J, Parada LF, Henkemeyer M: Receptor tyrosine kinase signaling in vascular development. Cell Growth Diff 8:3–10, 1997

    Google Scholar 

  3. Risau W:Mechanisms of angiogenesis. Nature, 386(17): 671–74, 1997

    Google Scholar 

  4. Beck L Jr, D'Amore PA: Vascular development: cellular and molecular regulation. FASEB J 11(5): 365–73, 1997

    Google Scholar 

  5. Plate K H, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 843–45, 1992

    Google Scholar 

  6. Fernig DG, Gallagher JT: Fibroblast growth factors and their receptors: an information network controlling tissue growth, morphogenesis and repair. Prog Growth Factor Res 5(4): 353–77, 1997

    Google Scholar 

  7. Klagsbrun M, D'Amore PA: Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 7(3):259–70, 1996

    Google Scholar 

  8. Battegay EJ, Rupp J, Iruela-Arispe L, Sage EH, Pech M: PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF ß-receptors. J Cell Biol125(4): 917–28,1994

    Google Scholar 

  9. Rohovsky SA, Hirschi KK, D'Amore PA: Growth factor effects on a model of vessel formation. Surg Forum 47: 390–91,1996

    Google Scholar 

  10. Panek RL, Lu GH, Klutchko SR, Batley BL, Dahring TK, Hamby JM, Hallak H, Dohert AM, Keiser JA: In vitro pharmacological characterization of PD166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J Pharm Exp Thera 283(3): 1433–44, 1997

    Google Scholar 

  11. Connolly CJ, Hamby JM, Schroeder MC, Barvian M, Lu GH, Panek RL, Amar A, Shen C, Kraker AJ, Fry DW, Klohs WD, Doherty AM: Discovery and structure-activity studies of a novel series of pyrido[2,3-D]pyrimidine tyrosine kinase inhibitors. Bioorg Med Chem Letters 7(18): 2415–20, 1997

    Google Scholar 

  12. Klohs WD, Steinkamph R, Driscoll D, Klutchko SR, Hamby, J, Lu GH, Vincent P, Roberts B, Elliott WL: Characterization of PDGF tyrosine kinase inhibitors in in vitro and in vivo tumors. Proc Amer Ass Can Res 38: 632, 1997

    Google Scholar 

  13. Hamby JM, Connolly CJ, Schroeder M, Winters R, Showalter H, Panek RL, Major T, Olsewski B, Ryan M, Dahring TK, Lu G, Keiser JA, Amar A, Shen C, Kraker AJ, Slintak V, Nelson JM, Fry DW, Bradford L, Hallak H, Doherty A M: Structure-activity relationships for a novel series of pyrido[2,3-D]pyrimidine tyrosine kinase inhibitors. J Med Chem 40(15): 2296–303, 1997

    Google Scholar 

  14. Mohammad M, Froum S, Hamby JM, Schroeder MC, Panek RL, Lu GH, Eliseenkova AV, Green D, Schlessinger J, Hubbard SR: Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 17(20):5896–904, 1998

    Google Scholar 

  15. Weishaupt KR, Gomer CJ, Dougherty TJ: Identification of singlet oxygen as the cytotoxic agent in the photoactivation of a murine tumor. Cancer Res 36: 2322–29, 1976

    Google Scholar 

  16. Kessel D: Sites of photosensitization by derivatives of hematoporphrin derivative. Photochem Photobiol 44: 489–93,1986

    Google Scholar 

  17. Gibson SL, Cohen HJ, Hilf R: Evidence against the production of superoxide by photoirradiation of hematoporphyrin. Photochem Photobiol 40: 441–48, 1984

    Google Scholar 

  18. Star WM, Marijnissen HP, van den Berg-Blok AE, Versteeg JA, Franken KA, Reinhold HS: Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. Cancer Res 46(5): 2532–40, 1986

    Google Scholar 

  19. Reed MW, Schuschke DA, Ackermann DM, Harty JI, Wieman TJ, Miller FN: The response of the rat urinary bladder microcirculation to photodynamic therapy. J Urology 142(3):865–68, 1989

    Google Scholar 

  20. Henderson BW, Dougherty TJ, Malone PB: Studies on the mechanism of tumor destruction by photodynamic therapy. In: D.R. Doiron and C.J. Gomer editors. Porphyrin localization and treatment of tumors. New York, Alan R. Liss, p. 601–12,1984

    Google Scholar 

  21. Beck TM, Hart NE, Woodard DA, Smith CE: Local or regionally recurrent carcinoma of the breast: results of therapy in 121 patients. J Clin Oncol 1(6): 400–5, 1983

    Google Scholar 

  22. Sperduto PW, DeLaney TF, Thomas G, Smith P, Dachowski LJ, Russo A, Bonner R, Glatstein E: Photodynamic therapy for chest wall recurrence in breast cancer. Int J Rad Onc Bio Phy 21(2): 441–6, 1991

    Google Scholar 

  23. Wilson CA, Saloupis P, Hatchell DL: Treatment of experimental preretinal neovascularization using photodynamic thrombosis. Invest. Ophthal & Vis Sci 32(9): 2530–5, 1991

    Google Scholar 

  24. Miller JW, Stinson WG, Gregory WA, el-Koumy HA, Puliafito CA: Phthalocyanine photodynamic therapy of experimental iris neovascularization. Ophthalmology 98(11): 1711–9, 1991

    Google Scholar 

  25. Leonessa F, Green D, Licht T, Wright A, Wingate-Legette K, Lippman J, Gottesman MM, Clarke R: MDA435/LCC6 and MDA/LCC6MDR1: ascites models of human breast cancer. Brit J Cancer 73: 154–61, 1996

    Google Scholar 

  26. Slovak M L, Ho JP, Bhardwaj G, Kurz EU, Deeley RG, Cole SP: Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines, Cancer Res 53(14): 3221–5, 1993

    Google Scholar 

  27. Fry DW, Kraker AJ, Connors RC, Elliott WL, Nelson JM, Showalter HD, Leopold WR: Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity. Anti-Cancer Drug Design 9(4): 331–51, 1994

    Google Scholar 

  28. Martiny-Baron G, Kazanietz mg, Mischak H, Blumberg PM, Kochs G, Hug H, et al.: Selective inhibition of protein kinase C isoenzymes by the indolocarbazole Go 6976. J Biol Chem 268: 9194–7, 1993

    Google Scholar 

  29. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR: New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening. J Natl Can Inst 82(13): 1107–12, 1990

    Google Scholar 

  30. Holford NH, Scheiner LB: Understanding the dose-effect relationship: Clinical applications of pharmacokineticpharmacodynamic models. J Clin Pharmocokin 6(6): 429–53,1981

    Google Scholar 

  31. Nash JC: Compact Numerical Method for Computers: Linear Algebra and Function Minimisation, New York: JohnWiley & Sons, 1979

    Google Scholar 

  32. Morales DE, McGowan KA, Grant DS, Maheshwari S, Bhartiya D, Cid MC, Kleinman HK, Schnaper HW: Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation 9(3): 755–63, 1995

    Google Scholar 

  33. Danesi R, Del Bianchi S, Soldani P, Campagni A, La Rocca RV, Myers CE, Paparelli A, Del Tacca M: Suramin inhibits bFGF-induced endothelial cells proliferation and angiogenesis in the chick chorioallantoic membrane. Brit J Cancer 68: 932–8, 1993

    Google Scholar 

  34. Kibbey MC, Grant DS, Kleinman HK: Role of the SIKVAV site of laminin in promotion of angiogenesis and tumor growth: an in vivo matrigel model. J Natl Can Inst 84(21):16633–8, 1992

    Google Scholar 

  35. Sharma A, Pizzolanti G, Oh L, Dougherty TJ, Bernacki RJ:Combination of photodynamic therapy and antiangiogenic therapy for the treatment of human breast cancer in nude athymic mice. Proc Amer Assoc Cancer Res 37: A1980, 1996

    Google Scholar 

  36. Henderson BW, Bellnier DA, Greco WR, Sharma A, Pandey RK, Vaughan LA, Weishaupt KR, Dougherty TJ: An in vivo quantitative structure-activity relationship for a congeneric series of pyropheophorbide derivatives as photosensitizers for photodynamic therapy. Cancer Res 57(18): 4000–7, 1997

    Google Scholar 

  37. Nicosia RF, Ottinetti A: Modulation of microvascular growth and morphogenesis by reconstituted basement membrane gel in three-dimensional cultures of rat aorta: a comparative study of angiogenesis in matrigel, collagen, fibrin, and plasma clot. In Vitro Cell Dev Bio 26(2): 119–28, 1990

    Google Scholar 

  38. Weidner N, Folkman J: Tumoral vascularity as a prognostic factor in cancer. Important Advances in Oncology 167–90, 1996

  39. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79(2): 185–88, 1994

    Google Scholar 

  40. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature (London)376: 62–66, 1995

    Google Scholar 

  41. Fong G, Rossant J, Gertsenstein M, Breitman ML: Role ofthe flt-1 receptor tyrosine kinase in regulating the assembly ofvascular endothelium. Nature (London) 376: 66–70, 1995

    Google Scholar 

  42. Soriano P: Abnormal kidney development and hematologicaldisorders in PDGF β-receptor mutant mice. Genes & Dev 8:1888–96, 1994

    Google Scholar 

  43. Schatteman GC, Motley ST, Effmann EL, Bowen-Pope DF:Platelet-derived growth factor receptor alpha subunit deletedpatch mouse exhibits severe cardiovascular dysmorphogenesis.Teratology 51: 351–66, 1995

    Google Scholar 

  44. Yamaguchi TP, Harpal K, Henkemeyer M, Rossant J: Fgfr-1is required for embryonic growth and mesodermal patterningduring mouse gastrulation. Genes & Dev 8(24): 3032–44,1994

    Google Scholar 

  45. Brunton VG, Kelland LR, Lear MJ, Montgomery GJ, Robertson JH, Robinson DJ, Queen J, Workman P: Synthesisand biological evaluation of a series of tyrphostins containingnitrothiophene moieties as possible epidermal growth factorreceptor tyrosine kinase inhibitors. Anti-Cancer Drug Design11(4): 265–95, 1996

    Google Scholar 

  46. Gazit A, Osherov N, Gilon C, Levitzki A: Tyrphostin.6. dimericbenzylidenemalononitrile tyrophostins-potent inhibitors of EGF receptor tyrosine kinase in vitro. J Med Chem 39(25):4905–11, 1996

    Google Scholar 

  47. Sawutz DG, Bode DC, Briggs GM, Reid JR, Canniff P, Caldwel lL, Faltynek CR, Miller D, Dunn JA, de Garavilla L, Guiles JW, Weigelt C, Michne W, Treasurywala AM, Silver PJ: In vitro characterization of a novel series of plateletderived growth factor receptor tyrosine kinase inhibitors.Biochem Pharm 51(12): 1631–8, 1996

    Google Scholar 

  48. Kohn EC, Liotta LA: Molecular insights into cancer invasion:strategies for prevention and intervention. Cancer Res55: 1856–62, 1995

    Google Scholar 

  49. Eckhardt SG, Pluda JM: Development of angiogenesis inhibitorsfor cancer therapy. Inv New Drugs 15: 1–3, 1997

    Google Scholar 

  50. Voest EE: Inhibitors of angiogenesis in a clinical perspective,Anti-Cancer Drugs 7: 723–7, 1996

    Google Scholar 

  51. Sharma A, Bernacki RJ: Ovarian cancer patients with CA-125 but no symptoms - Should antiangiogenic treatments beconsidered? Oncology Res 9(2): 53–4, 1997

    Google Scholar 

  52. Dimitroff CJ, Sharma A, Bernacki RJ: Cancer metastasis: asearch for therapeutic inhibition. Cancer Invest 16(4): 279–90,1998

    Google Scholar 

  53. Boehm T, Folkman J, Browder T, O'Reilly MS: Antiangiogenictherapy of experimental cancer does not induceacquired drug resistance, Nature 390(27): 404–7, 1997

    Google Scholar 

  54. Chang SC, Bown SG: Photodynamic therapy - applicationsin bladder cancer and other malignancies. J Form Med Assoc96(11): 853–63, 1997

    Google Scholar 

  55. Schuh M, Nseyo UO, Potter WR, Dao T, Dougherty TJ: Photodynamictherapy for palliation of locally recurrent breastcarcinoma. J Clin Onc 5(11): 1766–70, 1987

    Google Scholar 

  56. Khan SA, Dougherty TJ, Mang TS: An evaluation of photodynamictherapy in the management of cutaneous metastasis ofbreast cancer. Eur J Cancer 29A: 1686–90, 1993

    Google Scholar 

  57. Wilson BD, Mang TS, Stoll H, Jones C, Cooper M, Dougherty TJ: Photodynamic therapy for the treatment of basal cellcarcinoma. Arch Derm 128(12): 1597–601, 1992

    Google Scholar 

  58. Narayan S, Sivak MV. Jr: Palliation of esophageal carcinoma.Laser and photodynamic therapy. Chest Surg Clin North Amer4(2): 347–67, 1994

    Google Scholar 

  59. Nseyo UO, Dougherty TJ, Boyle DG, Potter WR, Wolf R, Huben R, Pontes JE: Whole bladder photodynamic therapyfor transitional cell carcinoma of the bladder, Urology 26(3):274–80, 1985

    Google Scholar 

  60. Dougherty TJ: Photodynamic therapy: status and potential.Oncology 3(7): 67–73, 1989

    Google Scholar 

  61. Dougherty TJ: Photodynamic therapy for early stage lungcancer. Preferable to resection? Chest 102(5): 1319–22, 1992

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Harvard Skin Disease Research Center, Harvard Medical School, Boston, MA, USA

    Charles J. Dimitroff, Paula Pera & Jean Veith

  2. Division of Warner-Lambert, Parke-Davis Pharm. Research, Ann Arbor, MI, USA

    Wayne Klohs, Denise Driscoll, Randall Steinkampf, Mel Schroeder & Sylvester Klutchko

  3. Department of Drug Metabolism and Pharmacokinetics, King of Prussia, SmithKline Beecham Pharmaceutical, PA, USA

    Amarnath Sharma

  4. Roswell Park Cancer Institute, Grace Cancer Drug Center, Department of Pharmacology and Therapeutics, USA

    Thomas J. Dougherty & Ralph J. Bernacki

  5. Department of Photodynamic Therapy, Buffalo, NY, USA

    Adam Sumlin & Barbara Henderson

Authors
  1. Charles J. Dimitroff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wayne Klohs
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amarnath Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paula Pera
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Denise Driscoll
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jean Veith
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Randall Steinkampf
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mel Schroeder
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sylvester Klutchko
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Adam Sumlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Barbara Henderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Thomas J. Dougherty
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Ralph J. Bernacki
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dimitroff, C.J., Klohs, W., Sharma, A. et al. Anti-Angiogenic Activity of Selected Receptor Tyrosine Kinase Inhibitors, PD166285 and PD173074: Implications for Combination Treatment with Photodynamic Therapy. Invest New Drugs 17, 121–135 (1999). https://doi.org/10.1023/A:1006367032156

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006367032156

Search

Navigation